Literature DB >> 23283517

Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models.

Fred Lühder1, Ralf Gold, Alexander Flügel, Ralf A Linker.   

Abstract

The concept of neuroprotective autoimmunity implies that immune cells, especially autoantigen-specific T cells, infiltrate the central nervous system (CNS) after injury and contribute to neuroregeneration and repair by secreting soluble factors. Amongst others, neurotrophic factors and neurotrophins such as brain-derived neurotropic factor (BDNF) are considered to play an important role in this process. New data raise the possibility that this concept could also be extended to neuroinflammatory diseases such as multiple sclerosis (MS) where autoantigen-specific T cells infiltrate the CNS, causing axonal/neuronal damage on the one hand, but also providing neuroprotective support on the other hand. In this review, we summarize the current knowledge on BDNF levels analyzed in MS patients in different compartments and its correlation with clinical parameters. Furthermore, new approaches in experimental animal models are discussed that attempt to decipher the functional relevance of BDNF in autoimmune demyelination.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283517     DOI: 10.1007/s00005-012-0211-0

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  11 in total

1.  Lower brain-derived neurotrophic factor levels associated with worsening fatigue in prostate cancer patients during repeated stress from radiation therapy.

Authors:  L N Saligan; N Lukkahatai; G Holder; B Walitt; R Machado-Vieira
Journal:  World J Biol Psychiatry       Date:  2015-03-27       Impact factor: 4.132

2.  Interaction between nonviral reprogrammed fibroblast stem cells and trophic factors for brain repair.

Authors:  G Liu; H Anisman; J Bobyn; S Hayley
Journal:  Mol Neurobiol       Date:  2014-03-28       Impact factor: 5.590

3.  Analysis of miRNA in Normal Appearing White Matter to Identify Altered CNS Pathways in Multiple Sclerosis.

Authors:  Mireia Guerau-de-Arellano; Yue Liu; Walter H Meisen; David Pitt; Michael K Racke; Amy E Lovett-Racke
Journal:  J Autoimmune Disord       Date:  2015

Review 4.  Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).

Authors:  Rachel E Klaren; Robert W Motl; Jeffrey A Woods; Stephen D Miller
Journal:  J Neuroimmunol       Date:  2014-06-24       Impact factor: 3.478

5.  Interferon-β Inhibits Neurotrophin 3 Signalling and Pro-Survival Activity by Upregulating the Expression of Truncated TrkC-T1 Receptor.

Authors:  Simona Dedoni; Maria C Olianas; Angela Ingianni; Pierluigi Onali
Journal:  Mol Neurobiol       Date:  2016-02-18       Impact factor: 5.590

6.  Serum levels of brain-derived neurotrophic factor (BNDF) in multiple sclerosis patients with Trichuris suis ova therapy.

Authors:  Berit Rosche; Jonas Werner; Friderike Joëlle Benzel; Lutz Harms; Heidi Danker-Hopfe; Rainer Hellweg
Journal:  Parasite       Date:  2013-12-19       Impact factor: 3.000

7.  Tristetraprolin is a novel regulator of BDNF.

Authors:  Anmol Kumar; Kärt Varendi; Johan Peränen; Jaan-Olle Andressoo
Journal:  Springerplus       Date:  2014-09-06

8.  Comprehensive catwalk gait analysis in a chronic model of multiple sclerosis subjected to treadmill exercise training.

Authors:  Danielle Bernardes; Alexandre Leite Rodrigues Oliveira
Journal:  BMC Neurol       Date:  2017-08-22       Impact factor: 2.474

9.  The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis.

Authors:  Emilio Portaccio; Angelo Bellinvia; Elio Prestipino; Benedetta Nacmias; Silvia Bagnoli; Lorenzo Razzolini; Luisa Pastò; Claudia Niccolai; Benedetta Goretti; Mattia Fonderico; Giovanni Bosco Zimatore; Nunzia Alessandra Losignore; Sandro Sorbi; Maria Pia Amato
Journal:  Front Neurol       Date:  2021-03-16       Impact factor: 4.003

10.  Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis.

Authors:  Nicolas Pelisch; Takashi Dan; Atsuhiko Ichimura; Hiroki Sekiguchi; Douglas E Vaughan; Charles van Ypersele de Strihou; Toshio Miyata
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.